Telomir Pharmaceuticals, Inc
Fundamentals
Oldest to newest| Line | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Net income | −$854,147 | −$13.1M | −$16.5M | −$10.4M |
| Operating cash flow | −$468,661 | −$3.9M | −$5.1M | −$3.7M |
| Shares outstanding | 26.8M | 28.6M | 29.8M | 34.4M |
| Line | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Net income | −$854,147 | −$13.1M | −$16.5M | −$10.4M |
| Operating cash flow | −$468,661 | −$3.9M | −$5.1M | −$3.7M |
| Shares outstanding | 26.8M | 28.6M | 29.8M | 34.4M |